UNSPSC 51124200: Antiarrythmic pyridines

This classification denotes substances based on a family of hexahydropyridines, substances called pyridines, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC pyridines.

UNSPSC 51124200 Antiarrhythmic pyridines, a Class code, describes emergency and acute-care medications that state and local procurement offices source for fire rescue, emergency medical services, and health agency operations. State and local governments buy these cardiac rhythm-management drugs through a mix of direct municipal purchase orders, multistate cooperative purchasing agreements, and state health agency procurement vehicles. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and Minnesota's multistate cooperative purchasing alliance have all posted opportunities recently, indicating that emergency-services departments, state health agencies, and cooperative purchasing administrators are the primary issuing bodies. Work under this code spans one-time sealed-bid procurements for specified drug quantities with firm expiration and delivery windows, market-intelligence requests from state agencies preparing to restructure their pharmacy benefit programs, and multivendor RFPs managed through cooperative purchasing networks that serve multiple state and local jurisdictions simultaneously.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa issued an ITB (Solicitation 26P00188) on April 24, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem totaling an estimated contract value of $40,000, with sealed bids due April 8, 2026, through the OpenGov eProcurement Portal and a one-year term plus optional renewals; the award includes a 5 percent bid discount sheltered for Small Local Business Enterprises, not to exceed $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer pharmacy contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award or budget disclosed. The Minnesota Department of Administration, administering MMCAP on behalf of multiple state and local participants including Oregon, issued an RFP (S1070000015802) with a March 26, 2026, proposal deadline for generic pharmaceuticals and OTC products through three authorized wholesalers; contract term is two years with evaluations weighted 75 percent on price competitiveness and 25 percent on compliance, pricing formats, and administrative capabilities, with effective dates of July 1, 2026, and performance penalties ranging from $200 to $1,500 per violation.